Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Patrick Y. Wen(Brigham and Women's Hospital), Michael Weller(University of Zurich), Eudocia Q. Lee(Brigham and Women's Hospital), Brian M. Alexander(Brigham and Women's Hospital), Jill S. Barnholtz‐Sloan(University Hospitals of Cleveland), Floris P Barthel(Jackson Laboratory), Tracy T. Batchelor(Brigham and Women's Hospital), Ranjit S. Bindra(Yale University), Susan M. Chang(University of California, San Francisco), E. Antonio Chiocca(Brigham and Women's Hospital), Timothy F. Cloughesy(University of California, Los Angeles), John DeGroot(The University of Texas MD Anderson Cancer Center), Evanthia Galanis(Mayo Clinic), Mark R. Gilbert(National Institutes of Health), Monika E. Hegi(University of Lausanne), Craig Horbinski(Northwestern University), Raymond Y. Huang(Brigham and Women's Hospital), Andrew B. Lassman(NewYork–Presbyterian Hospital), Émilie Le Rhun(Inserm), Michael Lim(Johns Hopkins University), Minesh P. Mehta(Miami Heart Research Institute), Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Giuseppe Minniti(University of Siena), David A. Nathanson(University of California, Los Angeles), Michael Platten(Heidelberg University), Matthias Preusser(Medical University of Vienna), Patrick Roth(University of Zurich), Marc Sanson(Centre National de la Recherche Scientifique), David Schiff(University of Virginia), Susan Short(University of Leeds), Martin Taphoorn(Leiden University Medical Center), Joerg-Christian Tonn(LMU Klinikum), Jonathan Tsang(University of California, Los Angeles), Roel G.W. Verhaak(Jackson Laboratory), Andreas von Deimling(German Cancer Research Center), Wolfgang Wick(Heidelberg University), Gelareh Zadeh(Princess Margaret Cancer Centre), David A. Reardon(Brigham and Women's Hospital), Kenneth Aldape(National Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute)
Neuro-Oncology
April 20, 2020
10.1093/neuonc/noaa106
Cited by 1,122Open Access
Full Text

Abstract

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

Related Papers

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
Agnes Lee, Mark N. Levine, Ross Baker et al.|New England Journal of Medicine|2003|2.5k
An extent of resection threshold for newly diagnosed glioblastomas
Nader Sanai, Mei‐Yin C. Polley, Michael W. McDermott et al.|Journal of neurosurgery|2011|1.6k
Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies
Jayne M. Stommel, Alec C. Kimmelman, Haoqiang Ying et al.|Science|2007|926
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Matija Snuderl, Ladan Fazlollahi, Long P. Le et al.|Cancer Cell|2011|707
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
David A. Nathanson, Beatrice Gini, Jack Mottahedeh et al.|Science|2013|684